Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 Dec;90(6):2574–2584. doi: 10.1172/JCI116152

Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia?

J Zapf 1, E Futo 1, M Peter 1, E R Froesch 1
PMCID: PMC443417  PMID: 1281841

Abstract

The pathogenesis of extrapancreatic tumor hypoglycemia has been related to the secretion of big insulin-like growth factor (IGF) II by the tumor. In 25 of 28 patients with this type of hypoglycemia we found 1.5-8-fold elevated serum levels of immunoreactive big (15-25 kD), but decreased levels of normal IGF II. After removal of the tumor, big IGF II disappeared and normal IGF II increased. Tumors contained elevated levels of IGF II, 65-80% in the big form. The insulin-like bioactivity of big IGF II and its affinity towards IGF-binding proteins (IGFBP)-2 and -3 are similar to those of normal IGF II, but two- to threefold higher on a molar basis. Big IGF II is mainly bound to the 50-kD IGFBP complex. The latter contains approximately 10 times more of this peptide than in normal serum and displays three- to fourfold increased insulin-like bioactivity. The formation of the 150-kD IGFBP complex with 125I-recombinant human IGFBP-3 is impaired in tumor serum. This results in sequestration of IGFBP-3 and predominant association of big IGF II with IGFBP-2 and -3 in the 50-kD complex. Increased bioavailability of big IGF II in this complex due to unrestricted capillary passage and enhanced insulin bioactivity of this big IGF II pool provide a continuous increased insulin-like potential available to insulin and type 1 IGF receptors of insulin-sensitive tissues and thus may lead to sustained hypoglycemia.

Full text

PDF
2574

Images in this article

2577Image
on p.2577
2580Image
on p.2580

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barzilai N., Cohen P., Bar-Illan R., McIntyre N., Karnieli E. Case report: increased insulin sensitivity in tumor hypoglycemia in a diabetic patient: glucose metabolism in tumor hypoglycemia. Am J Med Sci. 1991 Oct;302(4):229–234. doi: 10.1097/00000441-199110000-00007. [DOI] [PubMed] [Google Scholar]
  2. Baxter R. C., Daughaday W. H. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab. 1991 Oct;73(4):696–702. doi: 10.1210/jcem-73-4-696. [DOI] [PubMed] [Google Scholar]
  3. Binoux M., Hossenlopp P. Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J Clin Endocrinol Metab. 1988 Sep;67(3):509–514. doi: 10.1210/jcem-67-3-509. [DOI] [PubMed] [Google Scholar]
  4. Daughaday W. H., Emanuele M. A., Brooks M. H., Barbato A. L., Kapadia M., Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988 Dec 1;319(22):1434–1440. doi: 10.1056/NEJM198812013192202. [DOI] [PubMed] [Google Scholar]
  5. Daughaday W. H., Kapadia M. Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6778–6782. doi: 10.1073/pnas.86.17.6778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Daughaday W. H., Trivedi B., Kapadia M. Measurement of insulin-like growth factor II by a specific radioreceptor assay in serum of normal individuals, patients with abnormal growth hormone secretion, and patients with tumor-associated hypoglycemia. J Clin Endocrinol Metab. 1981 Aug;53(2):289–294. doi: 10.1210/jcem-53-2-289. [DOI] [PubMed] [Google Scholar]
  7. Gorden P., Hendricks C. M., Kahn C. R., Megyesi K., Roth J. Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. N Engl J Med. 1981 Dec 10;305(24):1452–1455. doi: 10.1056/NEJM198112103052405. [DOI] [PubMed] [Google Scholar]
  8. Gowan L. K., Hampton B., Hill D. J., Schlueter R. J., Perdue J. F. Purification and characterization of a unique high molecular weight form of insulin-like growth factor II. Endocrinology. 1987 Aug;121(2):449–458. doi: 10.1210/endo-121-2-449. [DOI] [PubMed] [Google Scholar]
  9. Guler H. P., Schmid C., Zapf J., Froesch E. R. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2868–2872. doi: 10.1073/pnas.86.8.2868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Guler H. P., Zapf J., Froesch E. R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 1987 Jul 16;317(3):137–140. doi: 10.1056/NEJM198707163170303. [DOI] [PubMed] [Google Scholar]
  11. Guler H. P., Zapf J., Schmid C., Froesch E. R. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989 Dec;121(6):753–758. doi: 10.1530/acta.0.1210753. [DOI] [PubMed] [Google Scholar]
  12. Hardouin S., Gourmelen M., Noguiez P., Seurin D., Roghani M., Le Bouc Y., Povoa G., Merimee T. J., Hossenlopp P., Binoux M. Molecular forms of serum insulin-like growth factor (IGF)-binding proteins in man: relationships with growth hormone and IGFs and physiological significance. J Clin Endocrinol Metab. 1989 Dec;69(6):1291–1301. doi: 10.1210/jcem-69-6-1291. [DOI] [PubMed] [Google Scholar]
  13. Haselbacher G. K., Irminger J. C., Zapf J., Ziegler W. H., Humbel R. E. Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1104–1106. doi: 10.1073/pnas.84.4.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Haselbacher G., Humbel R. Evidence for two species of insulin-like growth factor II (IGF II and "big" IGF II) in human spinal fluid. Endocrinology. 1982 May;110(5):1822–1824. doi: 10.1210/endo-110-5-1822. [DOI] [PubMed] [Google Scholar]
  15. Jakob A., Meyer U. A., Flury R., Ziegler W. H., Labhart A., Froesch E. R. The pathogenesis of tumour hypoglycaemia: blocks of hepatic glucose release and of adipose tissue lipolysis. Diabetologia. 1967 Dec;3(6):506–514. doi: 10.1007/BF01213569. [DOI] [PubMed] [Google Scholar]
  16. Jansen M., van Schaik F. M., van Tol H., Van den Brande J. L., Sussenbach J. S. Nucleotide sequences of cDNAs encoding precursors of human insulin-like growth factor II (IGF-II) and an IGF-II variant. FEBS Lett. 1985 Jan 7;179(2):243–246. doi: 10.1016/0014-5793(85)80527-5. [DOI] [PubMed] [Google Scholar]
  17. Joffe B., Kew M., Beaton G., Kusman B., Seftel H. Serum somatomedin and insulin levels in tumor hypoglycemia. J Endocrinol Invest. 1978 Jul;1(3):269–271. doi: 10.1007/BF03350392. [DOI] [PubMed] [Google Scholar]
  18. Kahn C. R. The riddle of tumour hypoglycaemia revisited. Clin Endocrinol Metab. 1980 Jul;9(2):335–360. doi: 10.1016/s0300-595x(80)80037-5. [DOI] [PubMed] [Google Scholar]
  19. King G. L., Kahn C. R., Rechler M. M., Nissley S. P. Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulinlike growth factor) using antibodies to the insulin receptor. J Clin Invest. 1980 Jul;66(1):130–140. doi: 10.1172/JCI109826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lowe W. L., Jr, Roberts C. T., Jr, LeRoith D., Rojeski M. T., Merimee T. J., Fui S. T., Keen H., Arnold D., Mersey J., Gluzman S. Insulin-like growth factor-II in nonislet cell tumors associated with hypoglycemia: increased levels of messenger ribonucleic acid. J Clin Endocrinol Metab. 1989 Dec;69(6):1153–1159. doi: 10.1210/jcem-69-6-1153. [DOI] [PubMed] [Google Scholar]
  21. Megyesi K., Kahn C. R., Roth J., Gorden P. Hypoglycemia in association with extrapancreatic tumors: demonstration of elevated plasma NSILA-s by a new radioreceptor assay. J Clin Endocrinol Metab. 1974 May;38(5):931–934. doi: 10.1210/jcem-38-5-931. [DOI] [PubMed] [Google Scholar]
  22. Merimee T. J. Insulin-like growth factors in patients with nonislet cell tumors and hypoglycemia. Metabolism. 1986 Apr;35(4):360–363. doi: 10.1016/0026-0495(86)90155-1. [DOI] [PubMed] [Google Scholar]
  23. Møller N., Blum W. F., Mengel A., Hansen L. B., Alberti K. G., Schmitz O. Basal and insulin stimulated substrate metabolism in tumour induced hypoglycaemia; evidence for increased muscle glucose uptake. Diabetologia. 1991 Jan;34(1):17–20. doi: 10.1007/BF00404019. [DOI] [PubMed] [Google Scholar]
  24. RANDLE P. J., GARLAND P. B., HALES C. N., NEWSHOLME E. A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963 Apr 13;1(7285):785–789. doi: 10.1016/s0140-6736(63)91500-9. [DOI] [PubMed] [Google Scholar]
  25. Ron D., Powers A. C., Pandian M. R., Godine J. E., Axelrod L. Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. J Clin Endocrinol Metab. 1989 Apr;68(4):701–706. doi: 10.1210/jcem-68-4-701. [DOI] [PubMed] [Google Scholar]
  26. Shapiro E. T., Bell G. I., Polonsky K. S., Rubenstein A. H., Kew M. C., Tager H. S. Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. J Clin Invest. 1990 May;85(5):1672–1679. doi: 10.1172/JCI114619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Stuart C. A., Prince M. J., Peters E. J., Smith F. E., Townsend C. M., 3rd, Poffenbarger P. L. Insulin receptor proliferation: a mechanism for tumor-associated hypoglycemia. J Clin Endocrinol Metab. 1986 Oct;63(4):879–885. doi: 10.1210/jcem-63-4-879. [DOI] [PubMed] [Google Scholar]
  28. Sussenbach J. S., Steenbergh P. H., Holthuizen P. Structure and expression of the human insulin-like growth factor genes. Growth Regul. 1992 Mar;2(1):1–9. [PubMed] [Google Scholar]
  29. Thomas P. S. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5201–5205. doi: 10.1073/pnas.77.9.5201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Unger R. H. The riddle of tumor hypoglycemia. Am J Med. 1966 Mar;40(3):325–330. doi: 10.1016/0002-9343(66)90127-6. [DOI] [PubMed] [Google Scholar]
  31. Widmer U., Zapf J., Froesch E. R. Is extrapancreatic tumor hypoglycemia associated with elevated levels of insulin-like growth factor II? J Clin Endocrinol Metab. 1982 Nov;55(5):833–839. doi: 10.1210/jcem-55-5-833. [DOI] [PubMed] [Google Scholar]
  32. Wing J. R., Panz V. R., Joffe B. I., Kalk W. J., Seftel H. C., Zapf J., Kew M. C. Hypoglycemia in hepatocellular carcinoma: failure of short-term growth hormone administration to reduce enhanced glucose requirements. Metabolism. 1991 May;40(5):508–512. doi: 10.1016/0026-0495(91)90232-l. [DOI] [PubMed] [Google Scholar]
  33. Zapf J., Kaufmann U., Eigenmann E. J., Froesch E. R. Determination of nonsuppressible insulin-like activity in human serum by a sensitive protein-binding assay. Clin Chem. 1977;23(4):677–682. [PubMed] [Google Scholar]
  34. Zapf J., Schmid C., Froesch E. R. Biological and immunological properties of insulin-like growth factors (IGF) I and II. Clin Endocrinol Metab. 1984 Mar;13(1):3–30. doi: 10.1016/s0300-595x(84)80006-7. [DOI] [PubMed] [Google Scholar]
  35. Zapf J., Schmid C., Guler H. P., Waldvogel M., Hauri C., Futo E., Hossenlopp P., Binoux M., Froesch E. R. Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia. J Clin Invest. 1990 Sep;86(3):952–961. doi: 10.1172/JCI114797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Zapf J., Schoenle E., Jagars G., Sand I., Grunwald J., Froesch E. R. Inhibition of the action of nonsuppressible insulin-like activity on isolated rat fat cells by binding to its carrier protein. J Clin Invest. 1979 May;63(5):1077–1084. doi: 10.1172/JCI109377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Zapf J., Schoenle E., Waldvogel M., Sand I., Froesch E. R. Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem. 1981 Jan;113(3):605–609. doi: 10.1111/j.1432-1033.1981.tb05105.x. [DOI] [PubMed] [Google Scholar]
  38. Zapf J., Walter H., Froesch E. R. Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest. 1981 Nov;68(5):1321–1330. doi: 10.1172/JCI110379. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES